CSPC PHARMA (01093) announced that, effective November 4, 2025, Mr. Pan Weidong has resigned as an executive director and ceased to serve as the company's authorized representative under Rule 3.05 of the Hong Kong Stock Exchange Listing Rules due to personal commitments requiring more time. Dr. Li Chunlei, an executive director of the company, has been appointed as the new authorized representative.